
The interview offers no high-conviction stock trade or price target; Databricks, Anthropic, and OpenAI are private, while the public companies mentioned lack specific buy or sell analysis. For public-market exposure, monitor Snowflake (SNOW) as a data-platform peer, but treat it as a watchlist idea—not a buy signal—without valuation or comparative analysis. Consider AI enterprise data infrastructure and cybersecurity as longer-term themes, while accounting for gradual adoption, rising AI costs, and security risks. Treat AI drug discovery partnerships involving Regeneron (REGN) and Merck (MRK) as developments to watch, not proven investment catalysts; clinical trials remain a key hurdle.

By All-In Podcast, LLC
Industry veterans, degenerate gamblers & besties Chamath Palihapitiya, Jason Calacanis, David Sacks & David Friedberg cover all things economic, tech, political, social & poker.